Hematology News

Edoxaban monotherapy for patients with atrial fibrillation and stable coronary disease reduced risk for adverse clinical events, mainly driven by lower bleeding risk, compared with dual antiplatelet therapy, a speaker reported.

Treatment of atrial fibrillation with asundexian, a novel factor XIa inhibitor, was associated with increased stroke and systemic embolism risk despite lower bleeding risk compared with apixaban, a speaker reported.

A year-long pilot program of external mentorship improved confidence, advanced career development and provided networking opportunities for classical hematology trainees, according to a study published in Blood Advances.

A platelet reactivity score that identifies people with a hyperreactive platelet phenotype can be used to determine those who might be at elevated risk for a cardiovascular event, researchers reported in Nature Communications.

More than half of people with iron deficiency continued to have low iron levels 3 years after diagnosis, according to retrospective study results.

Researchers at Boston Medical Center identified a new small molecule that could benefit people with sickle cell disease who do not respond to hydroxyurea.

Apixaban and aspirin offered similar protection against major ischemic and hemorrhagic events among people with cancer history and cryptogenic stroke.

Giroctocogene fitelparvovec reduced bleeding for men with moderately severe to severe hemophilia A, according to data released by the agent’s manufacturer.

Patients with acne who used benzoyl peroxide products did not have a risk for malignancy or increased blood benzene levels, according to a pair of studies published in the Journal of the American Academy of Dermatology.